WO2016070817A1 - 依达拉奉在制备用于预防和治疗脑淀粉样血管病的药物中的应用 - Google Patents
依达拉奉在制备用于预防和治疗脑淀粉样血管病的药物中的应用 Download PDFInfo
- Publication number
- WO2016070817A1 WO2016070817A1 PCT/CN2015/093837 CN2015093837W WO2016070817A1 WO 2016070817 A1 WO2016070817 A1 WO 2016070817A1 CN 2015093837 W CN2015093837 W CN 2015093837W WO 2016070817 A1 WO2016070817 A1 WO 2016070817A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- edaravone
- patient
- caa
- brain
- mice
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Definitions
- Figure 5 shows that edaravone inhibits the activity of BACE and Gsk-3 ⁇ .
- 1-5 edaravone significantly reduced the expression of CTF ⁇ and A ⁇ in the brain of AD mice
- 6-7 edaravone inhibited the expression and activity of BACE in the brain of AD mice, and enhanced the brain ⁇ of AD mice - the activity of secretase
- 8 Edaravone inhibits the activity of Gsk-3 ⁇ in the brain of AD mice
- 9-10 In vitro experiments further confirmed that edaravone inhibits the expression of BACE
- 11 In vitro experiments further confirmed that edaravone inhibits Gsk-3 ⁇ active.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (17)
- 依达拉奉或其类似物或衍生物在制备药物中的应用,其中通过向需要的患者给药,所述药物用于治疗脑淀粉样血管病(CAA)。
- 权利要求1的应用,其中所述药物通过静脉内、皮下或口服给药。
- 权利要求1的应用,其中所述药物制成针剂、片剂或胶囊剂。
- 权利要求1的应用,其中依达拉奉与其他治疗CAA的药物组合给药。
- 权利要求4的应用,其中所述其他药物为Aβ抗体。
- 权利要求1的应用,其中在药物给药前,还包括确定患者患有CAA。
- 权利要求6的应用,其中所述确定是确定患者罹患CAA的临床症状。
- 权利要求1的应用,其中所述患者的脑中有或者没有阿尔茨海默氏症的特征性斑块。
- 权利要求1的应用,其中所述患者有或者没有阿尔茨海默氏症的症状。
- 权利要求1的应用,其中所述患者有或者没有心脏病发作或中风。
- 权利要求1的应用,其中依达拉奉的日剂量在0.1mg/kg至25mg/kg之间。
- 依达拉奉或其类似物或衍生物在制备药物中的应用,其中通过向易患CAA的患者给药,所述药物用于预防CAA。
- 依达拉奉或其类似物或衍生物在制备药物中的应用,其中通过向需要的患者给药,所述药物用于减少该患者的血管淀粉样蛋白。
- 权利要求13的应用,其中所述给药按照与去除血管淀粉样蛋白相关或减少脑微出血发生率的治疗方案进行。
- 权利要求14的应用,其中所述治疗方案包括通过MRI监测患者的脑微出血。
- 权利要求14的应用,其中所述治疗方案包括通过PET扫描监测患者的血管淀粉样蛋白的去除或沉积。
- 权利要求14-16任一项的应用,其中所述治疗方案是长期治疗方案。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/523,855 US20170312253A1 (en) | 2014-11-05 | 2015-11-05 | Methods of preventing and treating cerebral amyloid angiopathy (caa) with an edaravone medicament |
EP15857765.0A EP3216447B1 (en) | 2014-11-05 | 2015-11-05 | Use of edaravone in preparing drug for preventing and treating cerebral amyloid angiopathy (caa) |
JP2017542258A JP6548738B2 (ja) | 2014-11-05 | 2015-11-05 | 脳アミロイド血管症の予防及び治療用医薬品を製造するためのエダラボンの使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410618300.6 | 2014-11-05 | ||
CN201410618300.6A CN105616405B (zh) | 2014-11-05 | 2014-11-05 | 依达拉奉在制备用于预防和治疗脑淀粉样血管病的药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016070817A1 true WO2016070817A1 (zh) | 2016-05-12 |
Family
ID=55908600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/093837 WO2016070817A1 (zh) | 2014-11-05 | 2015-11-05 | 依达拉奉在制备用于预防和治疗脑淀粉样血管病的药物中的应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20170312253A1 (zh) |
EP (1) | EP3216447B1 (zh) |
JP (1) | JP6548738B2 (zh) |
CN (1) | CN105616405B (zh) |
WO (1) | WO2016070817A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110381923A (zh) * | 2017-01-17 | 2019-10-25 | 萃微Tw001公司 | 包括肠内施用依达拉奉的医学治疗 |
CN108314652A (zh) * | 2017-01-18 | 2018-07-24 | 周意 | 依达拉奉衍生物及其用途 |
US11224389B2 (en) * | 2017-04-17 | 2022-01-18 | The Regents Of The University Of Colorado, A Body Corporate | Radiation transmission grid apparatus and methods for x-ray imaging detectors |
WO2019008144A1 (en) * | 2017-07-06 | 2019-01-10 | Treeway Tw001 B.V. | USE OF EDARAVONE IN THE ORAL TREATMENT OF NEURODEGENERATIVE DISORDERS INDUCED BY OXIDATIVE STRESS |
CN109985049B (zh) * | 2017-12-29 | 2022-02-22 | 广州市赛普特医药科技股份有限公司 | 5α-雄甾-3β,5,6β-三醇在制备治疗脑小血管病的药物中的应用 |
CN109431966B (zh) * | 2018-04-27 | 2020-09-22 | 首都医科大学附属北京天坛医院 | 依达拉奉药物组合物 |
WO2019213335A1 (en) * | 2018-05-04 | 2019-11-07 | Carnot2, Llc | Orally bioavailable prodrugs of edaravone with altered pharmacokinetic properties and methods of use thereof |
CA3118450A1 (en) * | 2018-10-31 | 2020-05-07 | Systamedic Inc. | Autophagy activators and inhibitors of ferroptosis for preventing acute renal failure and neurotoxcity induced by certain antibiotics |
CN115607545B (zh) | 2021-10-22 | 2023-11-10 | 苏州澳宗生物科技有限公司 | 依达拉奉在自闭症谱系障碍治疗中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA81216C2 (en) * | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US20060073149A1 (en) * | 2001-08-17 | 2006-04-06 | Bales Kelly R | Rapid improvement of cognition in condition related to abeta |
JP5259970B2 (ja) * | 2007-03-30 | 2013-08-07 | 学校法人九州文化学園 | 薬物依存症治療剤 |
JP2011136973A (ja) * | 2009-12-28 | 2011-07-14 | Keiki Imoto | 安定なエダラボン含有水性製剤 |
US20150297674A1 (en) * | 2012-03-12 | 2015-10-22 | Loma Linda University Medical Center | Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or disease |
CA2894178A1 (en) * | 2012-12-07 | 2014-06-12 | Biogen International Neuroscience Gmbh | A method of reducing brain amyloid plaques using anti-a.beta. antibodies |
-
2014
- 2014-11-05 CN CN201410618300.6A patent/CN105616405B/zh active Active
-
2015
- 2015-11-05 WO PCT/CN2015/093837 patent/WO2016070817A1/zh active Application Filing
- 2015-11-05 US US15/523,855 patent/US20170312253A1/en not_active Abandoned
- 2015-11-05 JP JP2017542258A patent/JP6548738B2/ja active Active
- 2015-11-05 EP EP15857765.0A patent/EP3216447B1/en active Active
Non-Patent Citations (2)
Title |
---|
SHEN YUE-E. ET AL.: "Effects of edaravone on amyloid-B precursor protein processing in sy5y-app695 cells", NEUROTOXICITY RESEARCH, vol. 24, no. 2, 17 January 2013 (2013-01-17), pages 139 - 147, XP055278284, ISSN: 1029-8428 * |
WANG, JIANHUA ET AL.: "Effects of Edaravone on the expressions of Abeta Tau and GFAP to the brain of vascular dementia in rat", CHINESE JOURNAL OF NEUROANATOMY, vol. 27, no. 2, 31 March 2011 (2011-03-31), pages 204, XP009502830, ISSN: 1000-7547 * |
Also Published As
Publication number | Publication date |
---|---|
EP3216447A4 (en) | 2018-06-27 |
CN105616405B (zh) | 2021-05-07 |
US20170312253A1 (en) | 2017-11-02 |
JP6548738B2 (ja) | 2019-07-24 |
EP3216447B1 (en) | 2021-06-02 |
JP2017533267A (ja) | 2017-11-09 |
EP3216447A1 (en) | 2017-09-13 |
CN105616405A (zh) | 2016-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016070817A1 (zh) | 依达拉奉在制备用于预防和治疗脑淀粉样血管病的药物中的应用 | |
Henstridge et al. | Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis | |
Chen et al. | Berberine mitigates cognitive decline in an Alzheimer’s Disease Mouse Model by targeting both tau hyperphosphorylation and autophagic clearance | |
JP6570597B2 (ja) | 新規方法 | |
Wang et al. | Chronic cerebral hypoperfusion induces memory deficits and facilitates Aβ generation in C57BL/6J mice | |
Christie et al. | Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy | |
Xu et al. | Luteolin promotes long-term potentiation and improves cognitive functions in chronic cerebral hypoperfused rats | |
Liu et al. | Neuronal Epac1 mediates retinal neurodegeneration in mouse models of ocular hypertension | |
Cai et al. | ACT001 attenuates microglia-mediated neuroinflammation after traumatic brain injury via inhibiting AKT/NFκB/NLRP3 pathway | |
CN111419870A (zh) | 使用环糊精的方法 | |
Zhao et al. | Trans-cinnamaldehyde improves neuroinflammation-mediated NMDA receptor dysfunction and memory deficits through blocking NF-κB pathway in presenilin1/2 conditional double knockout mice | |
Lu et al. | Methylprednisolone promotes recovery of neurological function after spinal cord injury: association with Wnt/β-catenin signaling pathway activation | |
US20210154156A1 (en) | Application of compound in inhibiting ab accumulation and treating alzheimer's disease | |
Xuan et al. | Berberine ameliorates rats model of combined Alzheimer’s disease and type 2 diabetes mellitus via the suppression of endoplasmic reticulum stress | |
Sanuki et al. | Normal aging hyperactivates innate immunity and reduces the medical efficacy of minocycline in brain injury | |
Xu et al. | Trehalose restores functional autophagy suppressed by high glucose | |
Matsuda et al. | Cholinergic modification of neurogenesis and gliosis improves the memory of AβPPswe/PSEN1dE9 Alzheimer’s disease model mice fed a high-fat diet | |
Hua et al. | Metformin increases cardiac rupture after myocardial infarction via the AMPK-MTOR/PGC-1α signaling pathway in rats with acute myocardial infarction | |
Wang et al. | Effects of JIP3 on epileptic seizures: evidence from temporal lobe epilepsy patients, kainic-induced acute seizures and pentylenetetrazole-induced kindled seizures | |
Dos Santos et al. | Cellular senescence in brain aging and neurodegeneration | |
Hu et al. | Sevoflurane postconditioning improves the spatial learning and memory impairments induced by hemorrhagic shock and resuscitation through suppressing IRE1α-caspase-12-mediated endoplasmic reticulum stress pathway | |
Zhang et al. | Propofol-induced developmental neurotoxicity: from mechanisms to therapeutic strategies | |
Zhao et al. | COG1410 regulates microglial states and protects retinal ganglion cells in retinal ischemia-reperfusion injury | |
He et al. | Immunotherapeutic effects of lymphocytes co-cultured with human cord blood-derived multipotent stem cells transplantation on APP/PS1 mice | |
Takase et al. | A pilot study of diabetic retinopathy in a porcine model of maturity onset diabetes of the young type 3 (MODY3) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15857765 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017542258 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15523855 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015857765 Country of ref document: EP |